(19)
(11) EP 3 436 606 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.03.2023 Bulletin 2023/11

(45) Mention of the grant of the patent:
22.02.2023 Bulletin 2023/08

(21) Application number: 17772917.5

(22) Date of filing: 31.03.2017
(51) International Patent Classification (IPC): 
C12Q 1/6883(2018.01)
C12N 15/10(2006.01)
C07H 21/04(2006.01)
C12P 19/34(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/10; C12Q 1/6883
(86) International application number:
PCT/CA2017/050405
(87) International publication number:
WO 2017/165982 (05.10.2017 Gazette 2017/40)

(54)

PLASMA DERIVED CELL-FREE MITOCHONDRIAL DEOXYRIBONUCLEIC ACID

ZELLFREIE MITOCHONDRIALE DESOXYRIBONUKLEINSÄURE AUS PLASMA

ACIDE DÉSOXYRIBONUCLÉIQUE MITOCHONDRIAL ACELLULAIRE DÉRIVÉ DU PLASMA


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 01.04.2016 US 201662317170 P

(43) Date of publication of application:
06.02.2019 Bulletin 2019/06

(73) Proprietor: M.A.G.I.C. Clinic Ltd.
Calgary AB T2E 7Z4 (CA)

(72) Inventors:
  • KHAN, Aneal
    Calgary, Alberta T2E 7Z4 (CA)
  • NEWELL, Christopher
    Calgary, Alberta T2L 2K7 (CA)
  • HUME, Stacey
    Edmonton, Alberta T6C 2H7 (CA)
  • GREENWAY, Steven
    Calgary, Alberta T2L 2K7 (CA)

(74) Representative: Hertin und Partner Rechts- und Patentanwälte PartG mbB 
Kurfürstendamm 54/55
10707 Berlin
10707 Berlin (DE)


(56) References cited: : 
CN-A- 105 087 767
CN-B- 101 270 390
   
  • Illumina: "Document # 15037958 v01 Human mtDNA Genome For the Illumina Sequencing Platform Revision History 1 Introduction 3 Workflow 5 Perform First Amplification 6 Quantify DNA 8 Tagment Input DNA 10 Perform Second Amplification 12 Perform Second DNA Clean Up 15 Bead-based Normalization 17 Pool Bead-Based No", , 1 February 2016 (2016-02-01), XP055615463, Retrieved from the Internet: URL:https://support.illumina.com/content/d am/illumina-support/documents/documentatio n/chemistry_documentation/samplepreps_lega cy/human-mtdna-genome-guide-15037958-01.pd f [retrieved on 2019-08-26]
  • CHRISTOPHER NEWELL ET AL: "Plasma-derived cell-free mitochondrial DNA: A novel non-invasive methodology to identify mitochondrial DNA haplogroups in humans", MOLECULAR GENETICS AND METABOLISM, vol. 125, no. 4, 1 December 2018 (2018-12-01), pages 332-337, XP055615617, AMSTERDAM, NL ISSN: 1096-7192, DOI: 10.1016/j.ymgme.2018.10.002
  • LIU, J. et al.: "Circulating cell -free mitochondrial deoxyribonucleic acid is increased in coronary heart disease patients with diabetes mellitus", J DIABETES INVESTIG, vol. 15, no. 1, 1 January 2016 (2016-01-01), pages 109-114, XP055578694, ISSN: 2040-1116, DOI: 10.1111/jdi.12366
  • XIA, P. et al.: "Simultaneous quantitative assessment of circulating cell -free mitochondrial and nuclear DNA by multiplex real-time PCR", GENETICS AND MOLECULAR BIOLOGY, vol. 32, no. 1, 1 January 2009 (2009-01-01), pages 20-24, XP055404314, DOI: doi:10.1590/S1415-47572009000100003
  • DE VLAMINCK, I. et al.: "Circulating Cell -Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection", SCI TRANS MED, vol. 6, no. 241, 18 June 2014 (2014-06-18) , pages 1-19, XP002744939, DOI: doi:10.1126/scitranslmed.3007803
  • HIDESTRAND, M. et al.: "Highly Sensitive Non-Invasive Cardiac Transplant Rejection Monitoring Using Targeted Quantification of Donor Specific Cell Free DNA", J AM COLL CARDIOL, vol. 63, no. 12, 1 April 2014 (2014-04-01) , pages 1224-1226, XP028831507, DOI: 10.1016/j.jacc.2013.09.029
  • EVANS, M. J. et al.: "Mitochondrial DNA genotypes in nuclear transfer-derived cloned sheep", NAT GENET, vol. 23, no. 1, 1 September 1999 (1999-09-01), pages 90-93, XP002946451, ISSN: 1061-4036, DOI: doi:10.1038/12696
  • KHAN, A. et al.: "An Algorithm Measuring Donor Cell -Free DNA in Plasma of Cellular and Solid Organ Transplant Recipients That Does Not Require Donor or Recipient Genotyping", FRONTIERS IN CARDIOVASCULAR MEDICINE, vol. 3, no. 33, 22 September 2016 (2016-09-22), pages 1-10, XP055440493, DOI: 10.3389/fcvm.2016.00033
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).